Physician profile
Tariq I Salim
NPI 1598293326
$3,671.24
in general payments reported to CMS, 2019-2025
27 companies · $1,190 in 2025
The $1,190 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $558 · 2023: $961 · 2024: $963 · 2025: $1,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,020 · Education: $93.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,019.55 |
| Education | $93.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,213.30 | 2022-2025 | Rinvoq, Creon, Mavyret |
| Janssen Biotech, INC. | $244.76 | 2023-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $187.16 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $177.44 | 2022-2025 | Entyvio |
| Cook Medical LLC | $153.76 | 2025 | Zilver Ptx |
| Lilly USA, LLC | $150.00 | 2023-2025 | Omvoh, Zepbound |
| Celgene Corporation | $127.07 | 2023-2024 | Zeposia |
| Ardelyx, INC. | $126.66 | 2024-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $124.98 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $121.34 | 2023-2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $118.76 | 2024 | Stelara |
| Conmed Corporation | $113.05 | 2022-2023 | Conmed Generators |
| Intercept Pharmaceuticals, INC. | $100.04 | 2023-2024 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.44 | 2023-2025 | Xifaxan |
| Daiichi Sankyo INC. | $79.99 | 2023-2025 | Injectafer |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $71.93 | 2024-2025 | Iqirvo, Bylvay |
| Genzyme Corporation | $70.55 | 2024-2025 | |
| Qol Medical, LLC | $69.87 | 2024 | Sucraid |
| Merck Sharp & Dohme LLC | $66.04 | 2023 | Dificid |
| Fresenius Kabi USA, LLC | $49.70 | 2023-2024 | Idacio |
| Phathom Pharmaceuticals, INC. | $47.84 | 2025 | Voquezna |
| Medtronic, INC. | $38.96 | 2025 | Interstim |
| Pfizer INC. | $38.65 | 2024-2025 | |
| Organon LLC | $34.80 | 2025 | Renflexis, Hadlima |
| Mauna Kea Technologies, INC. | $19.91 | 2024 | |
| Alnylam Pharmaceuticals INC. | $17.83 | 2025 | Givlaari |
| Ferring Pharmaceuticals INC. | $14.41 | 2024 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tariq Salim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.